iSpecimenISPC
ISPC
About: iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
Employees: 53
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
17% more funds holding
Funds holding: 6 [Q3] → 7 (+1) [Q4]
2.17% less ownership
Funds ownership: 5.9% [Q3] → 3.72% (-2.17%) [Q4]
48% less capital invested
Capital invested by funds: $183K [Q3] → $94.9K (-$88K) [Q4]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for ISPC.
Financial journalist opinion
Neutral
Newsfile Corp
1 month ago
iSpecimen Secures Suppliers for COVID-style hMPV Outbreak
Woburn, Massachusetts--(Newsfile Corp. - January 16, 2025) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, has secured suppliers for the flu-like human metapneumovirus (hMPV). The virus has been causing hospitals in China to become overrun, raising the potential for another COVID-style pandemic.
Neutral
Newsfile Corp
2 months ago
iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens
Woburn, Massachusetts--(Newsfile Corp. - December 20, 2024) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, today announced its strategic initiatives for 2025, expanding services to procure high demand cancer biospecimens, enhancing its ability to support groundbreaking cancer research worldwide. The demand for cancer tissue continues to grow as cancer remains a significant area of focus in medical research and investment.
Neutral
Newsfile Corp
2 months ago
iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers
Woburn, Massachusetts--(Newsfile Corp. - December 13, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today positive results attributed to its Next Day Quote Program ("NDQ"). This next-day quote service for researchers and providers is tailored to accelerate the biospecimen transaction process and delivers accurate biospecimen sample pricing within 24 hours of receiving the customer request.
Neutral
Newsfile Corp
2 months ago
iSpecimen Appoints Robert Lim as CEO and Director
Woburn, Massachusetts--(Newsfile Corp. - December 12, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it has appointed Robert Lim as CEO and director. Mr. Lim is the principal and co-founder of De Novo Law Corporation, a Vancouver-based law firm specializing in corporate/commercial law and civil litigation.
Neutral
Newsfile Corp
3 months ago
iSpecimen Named Top Competitor in $4.4 Billion USD Market
Biospecimen Market To Exceed $13.5 Billion USD By 2032 Woburn, Massachusetts--(Newsfile Corp. - November 8, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the addressable Biospecimen contract research services market is attractive and growing. In fact, according to AceInsight Analytic, the market is presently valued at USD 4.4 billion as of 2023 and is predicted to reach USD 13.5 billion by the year 2032, growing at a 13.3% CAGR during the forecast period.
Neutral
GlobeNewsWire
3 months ago
iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually
WOBURN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today a significant enhancement to its searchable inventory that provides researchers with increased access to a wide array of biospecimens vital to advancing oncology research and treatments.
Neutral
GlobeNewsWire
3 months ago
iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the closing of its previously announced public offering of approximately $5 million of the Company's common stock and pre-funded warrants to purchase shares of common stock at a public offering price of $3.00 per share (minus $0.0001 per pre-funded warrant). The Company intends to use the proceeds of the offering for repayment of outstanding debt, potential acquisitions of assets or investments in businesses, products and technologies and for marketing and advertising services. The remainder of the proceeds will be used for working capital purposes.
Neutral
GlobeNewsWire
3 months ago
iSpecimen Inc. Announces Pricing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
WOBURN, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the pricing of its public offering of approximately $5 million of the Company's common stock, and/or pre-funded warrants to purchase shares of common stock at a public offering price of $3.00 per share (minus $0.0001 per pre-funded warrant). The Company intends to use the proceeds of the offering for repayment of outstanding debt, potential acquisitions of assets or investments in businesses, products and technologies and for marketing and advertising services. The remainder of proceeds will be used for working capital purposes.
Neutral
GlobeNewsWire
4 months ago
iSpecimen Secures $1 Million Loan; Appoints Three New Board Members
WOBURN, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it has secured a $1 million loan agreement and subsequently appointed three new members to its Board of Directors.
Neutral
GlobeNewsWire
5 months ago
iSpecimen Announces 1-for-20 Reverse Stock Split
WOBURN, Mass., Sept. 11, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today that it will effect a reverse stock split of its issued and outstanding shares of common stock, par value $0.0001 per share, as well as any shares of common stock held by the Company in treasury, at a ratio of 1-for-20. The reverse stock split will become effective at 4:30 p.m. Eastern Time on September 13, 2024, and the Company's common stock will begin trading on a split-adjusted basis when the market opens on September 16, 2024. The Company's common stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol "ISPC." The new CUSIP number for the Company's common stock following the reverse stock split will be 45032V207.
Charts implemented using Lightweight Charts™